Compare MG & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MG | MRVI |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.7M | 559.0M |
| IPO Year | 2008 | 2020 |
| Metric | MG | MRVI |
|---|---|---|
| Price | $17.33 | $4.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 169.4K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $700,970,000.00 | $185,743,000.00 |
| Revenue This Year | $5.47 | $12.54 |
| Revenue Next Year | $3.59 | $7.87 |
| P/E Ratio | $251.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.38 | $1.99 |
| 52 Week High | $19.56 | $5.00 |
| Indicator | MG | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 68.22 |
| Support Level | $16.40 | $3.27 |
| Resistance Level | $19.46 | $5.00 |
| Average True Range (ATR) | 0.67 | 0.25 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 56.63 | 81.91 |
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.